Etoposide: four decades of development of a topoisomerase II inhibitor (Q28294370)

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Interaction between DNA and an Escherichia coli protein omega

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

DNA gyrase: an enzyme that introduces superhelical turns into DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

The clinical pharmacology of etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

VP-16-213 (etoposide): the mandrake root from Issyk-Kul

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Current status of etoposide in the management of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Etoposide. Current and future status

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

New chemotherapies for ovarian cancer. Systemic and intraperitoneal podophyllotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Current strategies in the management of locoregional and metastatic gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Etoposide in the management of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

EPEG, a new antineoplastic epipodophyllotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

PTG, a new antineoplastic epipodophyllotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Etoposide kinetics in patients with obstructive jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Predicting etoposide toxicity: relationship to organ function and protein binding

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Pharmacodynamic modeling of prolonged administration of etoposide.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Bioavailability of low-dose oral etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Pharmacological attempts to improve the bioavailability of oral etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

The importance of drug scheduling in cancer chemotherapy: etoposide as an example

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Phase I clinical and pharmacokinetic study of oral etoposide phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Adriamycin-dependent release of iron from microsomal membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Mitoxantrone: an overview of safety and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Topoisomerase inhibitors. A review of their therapeutic potential in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021

Antitopoisomerase drug action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900228-7

7 January 2021